Copyright © 2003 by the European Society of Cardiology.
Editorial
Blood pressure lowering and ACE inhibition for the avoidance of cardiac and cerebral events
Institute for International Health, University of Sydney, P.O. Box 576, 2042 Sydney, New South Wales, Australia
* Corresponding author. Tel.: +61-2-9351-0099; fax: +61-2- 9351-0008
E-mail address: s.macmahon@iih.usyd.edu.au
| The first 10% of the full text of this article appears below. |
See doi:10.1016/S1095-668X(02)00804-7for the article to which this editorial refers.
It is now well established that the level of blood pressure, whether systolic or diastolic, is an important determinant of the risks of both stroke and heart attacknot only among those with high blood pressure but also among those with average or below average blood pressure levels.1 However, while numerous clinical trials have demonstrated that blood pressure lowering treatments reduce the risks of stroke and of heart attack in hypertensives,2,3 until recently there has been little evidence about the effects of such therapy in non-hypertensives. Since many individuals at very high risk of stroke or heart attack do not have hypertension, there is
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease
- PROGRESS Collaborative Group
EHJ 2003 24: 475-484.[Abstract] [FREE Full Text]
This article has been cited by other articles:
![]() |
J. J. Brugts, T. Ninomiya, E. Boersma, W. J. Remme, M. Bertrand, R. Ferrari, K. Fox, S. MacMahon, J. Chalmers, and M. L. Simoons The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials Eur. Heart J., June 1, 2009; 30(11): 1385 - 1394. [Abstract] [Full Text] [PDF] |
||||
